Difficulty: Medium
Average Score: 95%
Practice
A nurse treating chronic asthmatic patients with methylxanthines must remember to increase the dosage when prescribing this medication simultaneously with
Correct answer
B
Rationale
In pharmacology, understanding drug interactions is crucial to ensure safe and effective patient care. In this scenario, the correct answer is B) Phenobarbital, phenytoin, and rifampin. These medications are known to induce hepatic enzymes, specifically CYP1A2, which is responsible for the metabolism of methylxanthines like theophylline. When these enzyme-inducing drugs are taken concurrently with methylxanthines, they can increase the metabolism of methylxanthines, leading to decreased therapeutic levels and potentially reduced efficacy. Therefore, increasing the dosage of methylxanthines is necessary to maintain therapeutic effects in chronic asthmatic patients.
Option A) Cimetidine, ciprofloxacin, and other fluoroquinolone antibiotics are actually inhibitors of CYP1A2, leading to potential increased levels of methylxanthines when taken together. This could result in toxic effects and requires a reduction in the methylxanthine dosage.
Option C) Albuterol and TCAs do not have a significant impact on the metabolism of methylxanthines. Albuterol is a bronchodilator commonly used in asthma management, while TCAs (tricyclic antidepressants) do not interact significantly with methylxanthines in terms of metabolism.
Option D) None of the listed drugs pose a risk when taken concurrently with methylxanthines is incorrect because as explained above, there are specific drugs like phenobarbital, phenytoin, and rifampin that can affect the metabolism of methylxanthines and require dosage adjustments.
Understanding these drug interactions is essential for nurses and healthcare providers to prevent adverse effects and ensure optimal patient outcomes. It highlights the importance of medication reconciliation, monitoring for interactions, and individualizing patient care based on their specific medication regimen and conditions.
Option A) Cimetidine, ciprofloxacin, and other fluoroquinolone antibiotics are actually inhibitors of CYP1A2, leading to potential increased levels of methylxanthines when taken together. This could result in toxic effects and requires a reduction in the methylxanthine dosage.
Option C) Albuterol and TCAs do not have a significant impact on the metabolism of methylxanthines. Albuterol is a bronchodilator commonly used in asthma management, while TCAs (tricyclic antidepressants) do not interact significantly with methylxanthines in terms of metabolism.
Option D) None of the listed drugs pose a risk when taken concurrently with methylxanthines is incorrect because as explained above, there are specific drugs like phenobarbital, phenytoin, and rifampin that can affect the metabolism of methylxanthines and require dosage adjustments.
Understanding these drug interactions is essential for nurses and healthcare providers to prevent adverse effects and ensure optimal patient outcomes. It highlights the importance of medication reconciliation, monitoring for interactions, and individualizing patient care based on their specific medication regimen and conditions.